VUM-02

It is a phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of VUM02 Injection in patients with acute graft-versus-host disease (aGvHD) who have failed systemic steroid therapy. VUM02 Injection (human umbilical cord-derived mesenchymal stromal /stem cells, hUC-MSC) is an off-the-shelf allogeneic cell therapy product comprising culture-expanded mesenchymal stromal /stem cells derived from the human umbilical cord tissue. The product is cryopreserved with the cell concentration of 5 x 10^6 cells/mL. Patients with grade II to IV aGvHD who have failed systemic steroid therapy (i.e. patients with steroid-refractory aGvHD (SR-aGvHD)), will be recruited into this study. This study consists of two phases, a dose-escalation phase (phase I) and a dose-expansion phase (phase II).

主要研究目的： 评价不同剂量的VUM02注射液治疗特发性肺纤维化（IPF）的安全性、耐受性。 次要研究目的： 1）评价不同剂量的VUM02注射液治疗特发性肺纤维化（IPF）的初步有效性，为后续临床研究推荐合适的细胞治疗剂量。 2）探索VUM02注射液治疗特发性肺纤维化（IPF）的免疫相关特征。